Snca targeted antisense oligonucleotides mediate progression of pathological deposition in alpha synuclein rodent transmission models of Parkinson's disease

被引：0
|
作者：
Cole, Tracy [2 ]
Paumier, Katrina [3 ]
Zhao, Hien [2 ]
Weihofen, Andreas [1 ]
Kordasiewicz, Holly [2 ]
Swayze, Eric [2 ]
机构：
[1] Biogen, Neurol Res, Cambridge, MA USA
[2] ISIS Pharmaceut, Neurosci Drug Discovery, 2280 Faraday Ave, Carlsbad, CA 92008 USA
[3] Michigan State, Translat Sci & Mol Med, Grand Rapids, MI USA
来源：
NEUROLOGY | 2016年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P6.239
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Outlook of SNCA (α-synuclein) transgenic fly models in delineating the sequel of mitochondrial dysfunction in Parkinson's disease
    Samson, Jennifer Sally
    Rajagopal, Kalyanaraman
    Parvathi, Venkatachalam Deepa
    BRAIN RESEARCH, 2025, 1852
  • [22] Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid Downregulate SNCA Expression and Improve Motor Function in Parkinson's disease Mouse Models
    Uehara, T.
    Choong, C. J.
    Hayakawa, H.
    Kasahara, Y.
    Nagata, T.
    Yokota, T.
    Baba, K.
    Nakamori, M.
    Obika, S.
    Mochizuki, H.
    MOVEMENT DISORDERS, 2017, 32
  • [23] SNCA variants and alpha-synuclein level in CD45+blood cells in Parkinson's disease
    Emelyanov, A.
    Kulabukhova, D.
    Garaeva, L.
    Senkevich, K.
    Verbitskaya, E.
    Nikolaev, M.
    Andoskin, P.
    Kopytova, A.
    Milyukhina, I
    Yakimovskii, A.
    Timofeeva, A.
    Prakhova, L.
    Ilves, A.
    Vlasova, I
    Pchelina, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 395 : 135 - 140
  • [24] LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model
    Zhao, Hien Tran
    John, Neena
    Delic, Vedad
    Ikeda-Lee, Karli
    Kim, Aneeza
    Weihofen, Andreas
    Swayze, Eric E.
    Kordasiewicz, Holly B.
    West, Andrew B.
    Volpicelli-Daley, Laura A.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2017, 8 : 508 - 519
  • [25] Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders
    Tolmasov, Michael
    Djaldetti, Ruth
    Lev, Nirit
    Gilgun-Sherki, Yossi
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 505 - 513
  • [26] Pathological Pathways and Alpha-Synuclein in Parkinson's Disease: A View from the Periphery
    Basellini, Milo Jarno
    Kothuis, Josine Marie
    Comincini, Alessandro
    Pezzoli, Gianni
    Cappelletti, Graziella
    Mazzetti, Samanta
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2023, 28 (02):
  • [27] A Noble Pathological Role for Alpha-Synuclein in Triggering Neurodegeneration of Parkinson's Disease
    Bahiraee, Alireza
    Ebrahimi, Reyhane
    MOVEMENT DISORDERS, 2018, 33 (03) : 404 - 404
  • [28] Selective Suppression of α-Synuclein in Monoaminergic Neurons of Mice by Intranasal Delivery of Targeted Small Interfering RNA or Antisense Oligonucleotides: Potential Therapy for Parkinson's Disease
    Recasens, Ariadna
    Galofre, Mireia
    Carballo-Carbajal, Iria
    Ferres-Coy, A.
    Bove, Jordi
    Perier, Celine
    del Carmen Carmona, Maria
    Santos, M. I.
    Baena, S.
    Rosario Chica, M.
    Montefeltro, Andres P.
    Revilla, R.
    Bortolozzi, Analia
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S419 - S420
  • [29] Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease
    Gallegos, Scarlet
    Pacheco, Carla
    Peters, Christian
    Opazo, Carlos M.
    Aguayo, Luis G.
    FRONTIERS IN NEUROSCIENCE, 2015, 9
  • [30] Enhancing the Proteasomal Degradation of Alpha Synuclein: "The Hallmark" to attenuating the Progression of Parkinson's Disease
    Adebisi, B.
    Adeleke, M.
    MOVEMENT DISORDERS, 2019, 34 : S302 - S302
12345